Pacira BioSciences, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$22.16
+$0.25 (+1.14%) Close
Prev closePrevC$21.91
OpenOpen$21.93
Day highHigh$22.16
Day lowLow$21.93
VolumeVol258
Avg volAvgVol930,479
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$900.50M
P/E ratio
48.17
FY Revenue
$716.79M
EPS
0.46
Gross Margin
79.17%
Sector
Healthcare
AI report sections
MIXED
PCRX
Pacira BioSciences, Inc.
Pacira BioSciences shows improving short-term price momentum against a backdrop of negative 6–12 month returns and a price still below its 50-day moving average. Fundamentals reflect high gross margins, expanding earnings, and solid free cash flow generation, offset by modest profitability ratios and a relatively high earnings multiple. Short interest is elevated with a high days-to-cover figure, while recent news flow around its non-opioid and corticosteroid-related portfolio appears generally constructive.
Corticosteroids Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031
The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.
GSKPCRXOCULABBVcorticosteroids marketasthmaCOPDdrug delivery systems
Sentiment note
ZILRETTA extended-release injection generated $118.1 million in net product sales in 2024, reflecting successful commercialization of advanced localized delivery technology for osteoarthritis pain management.
NeutralGlobeNewswire Inc.• Pacira Biosciences, Inc.
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
Pacira BioSciences received a Paragraph IV Certification Notice from Qilu Pharmaceutical regarding a generic equivalent filing for EXPAREL, challenging 18 of Pacira's patents. Pacira intends to vigorously defend its intellectual property rights.
Company is proactively responding to a potential patent challenge by preparing legal action to protect its intellectual property
PositiveGlobeNewswire Inc.• Pacira Biosciences, Inc.
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.
Company is presenting multiple research studies demonstrating the clinical and economic value of their non-opioid pain management solutions, indicating strong research and innovation capabilities
PositiveGlobeNewswire Inc.• Pacira Biosciences, Inc.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to 15 new employees, including 18,000 stock options and 32,600 restricted stock units, to incentivize new hires under their Inducement Plan.
The company is actively hiring and investing in new talent by offering substantial equity compensation, indicating growth and confidence in future prospects
PositiveGlobeNewswire Inc.• Pacira Biosciences, Inc.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted stock options and restricted stock units to nine new employees under its Inducement Plan, with 13,000 stock options and 18,100 restricted stock units awarded.
The company is expanding its workforce and offering competitive equity compensation, indicating growth and financial stability
PositiveGlobeNewswire Inc.• N/A
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
Pacira BioSciences debuted a new film at the BIO 2025 convention, highlighting the journey of a couple who found relief from chronic pain through non-opioid treatments. The film showcases the impact of innovative pain management solutions and the importance of patients having options beyond opioids.
The article highlights Pacira BioSciences' commitment to developing and promoting innovative, non-opioid pain management solutions, which is seen as a positive step in addressing the opioid crisis and improving patient outcomes.
NegativeGlobeNewswire Inc.• Grabar Law Office
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of DoubleVerify, NAPCO, Pacira Biosciences, and Treace Medical Concepts.
DVNSSCPCRXTMCIDoubleVerifyNAPCOPacira BiosciencesTreace Medical Concepts
Sentiment note
The article indicates that Grabar Law Office is investigating whether Pacira's officers and directors breached their fiduciary duties, as a securities fraud class action complaint alleges the company made false and misleading statements about the validity and scope of its patents.
NegativeGlobeNewswire Inc.• N/A
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
Pacira BioSciences, Inc. is facing a securities class action lawsuit due to alleged false and/or misleading statements about the patent protection of its drug Exparel, which led to investor losses.
PCRXPacira BioSciencessecurities class actionpatent protectionExparel
Sentiment note
The article discusses a securities class action lawsuit against Pacira BioSciences, alleging that the company made false and/or misleading statements about the patent protection of its drug Exparel, which led to investor losses.
NegativeGlobeNewswire Inc.• N/A
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ: PCRX) after the company's '495 patent was invalidated, leading to a significant drop in its stock price.
The article reports that Pacira's '495 patent was invalidated, leading to a significant drop in its stock price, which is a negative development for the company.
PositiveGlobeNewswire Inc.• N/A
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. announced the granting of inducement awards to six new employees, including stock options and restricted stock units, as a material inducement to their employment with the company.
PCRXPacira BioSciencesinducement awardsstock optionsrestricted stock units
Sentiment note
The article announces that Pacira BioSciences is granting inducement awards to new employees, which is a positive sign for the company's growth and ability to attract talent.
NegativeGlobeNewswire Inc.• Claimsfiler
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Pacira BioSciences, Inc. is facing a class action lawsuit due to its failure to disclose material information during the class period, resulting in a significant drop in its stock price.
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Pacira BioSciences, Inc. is facing a class action lawsuit due to its failure to disclose material information during the class period, resulting in a significant drop in its stock price.
The article reports that Pacira BioSciences is facing a class action lawsuit for failing to disclose material information, which led to a significant drop in its stock price. This suggests negative sentiment towards the company's actions and potential legal and financial consequences.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
